The Role of Prolactin and the Diagnostic Value of Hyperprolactinemia in Men

І. І. Горпинченко, В. В. Спиридоненко


Verification of the clinical cause and therapy of pathologically elevated prolactin levels is a pressing problem of modern andrology, which the andrologist and sexopathologist increasingly face, which requires a correct and competent approach to diagnosis and therapy.


hyperprolactinemia; male infertility


Сексология и андрология / под ред. А.Ф. Возианова, И.И. Горпинченко. – К.: Абрис, 1997. – 880 с.

Salais-López H, Agustín-Pavón C, Lanuza E, Martínez-García F. (2018) The maternal hormone in the male brain: Sexually dimorphic distribution of prolactin signalling in the mouse brain. PLoS One. Dec 20;13(12): e0208960.

Татарчук Т.Ф., Гуньков С.В., Ефименко О.А. Современные подходы к диагностике и лечению гиперпролактинемии // Репродуктивная эндокринология. – 2012. – № 1. – С. 26–44.

Clapp C. et al. (2015) Regulation of blood vessels by prolactin and vasoinhibins // Advances in experimental medicine and biology. Vol. 846. – P. 83–95.

Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R et al. (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med; 44 (Suppl.):1075–84.

Majumdar A., Mangal N.S. (2013) Hyperprolactinemia J Hum Reprod Sci, 6. pp. 168–175.

Melmed S., Kleinberg D (2008) Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR eds. Williams textbook of endocrinology . 11th ed. Philadelphia: Saunders Elsevier; 185–261.

Modebe O. (1994) Hyperprolactinemia in oligospermic Nigerian males: effect of bromocriptine treatment Int J Fertil Menopausal Stud, 39. pp. 95–99.

Rosa De M., Ciccarelli A., Zarrilli S., Guerra E., Gaccione M., Di Sarno A. et al. (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males Clin Endocrinol (Oxf), 64, pp. 307–313.

Colao A., Vitale G., Cappabianca P., Briganti F., Ciccarelli A., De Rosa M., et al. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis J Clin Endocrinol Metab, 89, pp. 1704–1711.

Rosa De M., Colao A., Di Sarno A., Ferone D., Landi M.L., Zarrilli S. et al. (1998) Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol, 138. pp. 286–293.

Bandyopadhyay A., Sen K., Chakrabarti N., Datta S. (2019) Galactocele of adult male breast: A cytopathologist’s perspective. Diagn Cytopathol. Feb;47(2):134–136.

Molitch M.E. (2008) Drugs and prolactin Pituitary, 11. pp. 209–218.

Katznelson L., Klibanski A. (1997) Prolactinomas Cancer Treat Res, 89. pp. 41–55.

Colao A., De Rosa M., Sarnacchiaro F., Di Sarno A., Landi M.L., Iervolino E., et al. (1996) Chronic treatment with CV 205–502 restores the gonadal function in hyperprolactinemic males Eur J Endocrinol, 135. pp. 548–552.

Singh P., Singh M., Cugati G., Singh A.K. (2011) Hyperprolactinemia: an often missed cause of male infertility J Hum Reprod Sci, 4. pp. 102–103.

Nishimura K., Matsumiya K., Tsuboniwa N., Yamanaka M., Koga M., Miura H. Et al. (1999) Bromocriptine for infertile males with mild hyperprolactinemia: hormonal and spermatogenic effects Arch Androl, 43. pp. 207–213.

Mcquaid J.W., Tanrikut C. (2014) Physiology of testosterone. In: Mulhall JP, Hsiao W, editors. Men’s sexual health and fertility. A Clinician’s guide. New York: Springer Science and Business Media.

Tsutsumi R., Webster N.J. (2009) GnRH pulsatility, the pituitary response and reproductive dysfunction Endocr J, 56. pp. 729–737.

Hair W.M., Gubbay O., Jabbour H.N., Lincoln G.A. (2002) Prolactin receptor expression in human testis and accessory tissues: localization and function. Mol Hum Reprod.; 8:606–11.

Klemcke H.G., Amador A.G., Bartke A. (1990) Hormonal regulation of testicular prolactin receptors and testosterone synthesis in golden hamsters Biol Reprod, 43, pp. 162–168.

Jabbour H.N., Lincoln G.A. (1999) Prolactin receptor expression in the testis of the ram: localisation, functional activation and the influence of gonadotrophins Mol Cell Endocrinol, 148, pp. 151–161.

Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A. et al. (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab, 96, pp. 273–288.

Furigo IC, Suzuki MF, Oliveira JE et al. (2019) Suppression of Prolactin Secretion Partially Explains the Antidiabetic Effect of Bromocriptine in ob/ob Mice. Endocrinology. Jan 1;160(1):193–204.

Iglesias P, Arcano K, Berrocal VR, Bernal C, Villabona C, Díez JJ. (2018) Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes. Horm Metab Res. Nov;50(11):791–796.

Lazopoulos A., Krimiotis D., Schizas N.C. et al. (2018) Galactorrhea, mastodynia and gynecomastia as the first manifestation of lung adenocarcinoma. A case report. Respir Med Case Rep. Dec 4;26:146–149.

Salhi H., Lahlou A., Dante M.L., El Ouahabi H., Boujraf S., Ajdi F. (2018) Stature-weight growth delays: Clinical and etiological aspects. J Family Med Prim Care. Sep-Oct;7(5):963–966.

Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology. Evaluation of the azoospermic male: a committee opinion. (2018) Fertil Steril. May;109(5):777–782.

Maiter D. (2018) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019;109(1):42–50.

Pinzone J.J., Katznelson L., Danila D.C., Pauler D.K., Miller C.S., Klibanski A. (2000) Primary medical therapy of micro- and macroprolactinomas in men J Clin Endocrinol Metab, 85 pp. 3053–3057.

RxList. Dostinex (cabergoline); 2016. Available at: Accessed October 2017.

RxList. Cycloset (bromocriptine mesylate tablets), 2017. Available at: Accessed October 2017.

Barlier A., Jaquet P. (2006) Quinagolide – a valuable treatment option for hyperprolactinaemia Eur J Endocrinol, 154. pp. 187–195.

Colao A., Di Sarno A., Cappabianca P., Di Somma C., Pivonello R., Lombardi G. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia N Engl J Med, 349. pp. 2023–2033.

Copyright (c) 2020 І. І. Горпинченко, В. В. Спиридоненко

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-5547 (Online), ISSN 2307-5090 (Print)